Copyright Marchini et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
A17-signatures are enriched in bone metastasis and are up-regulated after hormonal therapy in ER-positive tumors.
Module map analysis of public available microarray dataset of human metastatic tumors disseminated from primary breast cancers demonstrated that A17-signatures were significantly over-represented in bone metastasis samples and under-expressed in brain metastasis samples (a). Module map analysis on murine xenotransplats of breast tumor cells before and after hormonal therapy showed that A17-signatures were significantly under-represented in samples before treatment (b). Hierarchical clusterization for a restricted gene set of epithelial, basal-like and mesenchymal markers (c) showed that the highest percentages of ‘after treatment’ samples fell in two clusters, which were characterized by the higher-then-median expression of HER-2 and KRT5, respectively.